AAP
SAGE

Aristotle Atlantic Partners’s Sage Therapeutics SAGE Stock Holding History

Aristotle Atlantic Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-197,626
Closed -$9.29M – 104
2023
Q2 		$9.29M Buy
197,626
+41,107
+26% +$2.05M 0.35% 61
2023
Q1 		$6.57M Buy
156,519
+422
+0.3% +$18.1K 0.34% 66
2022
Q4 		$5.95M Sell
156,097
-381
-0.2% -$14.6K 0.33% 67
2022
Q3 		$6.13M Buy
156,478
+1,360
+0.9% +$52.6K 0.37% 66
2022
Q2 		$5.01M Buy
155,118
+3,015
+2% +$101K 0.39% 61
2022
Q1 		$5.04M Buy
152,103
+1,206
+0.8% +$45.3K 0.31% 68
2021
Q4 		$6.42M Sell
150,897
-10,393
-6% -$435K 0.37% 63
2021
Q3 		$7.15M Buy
161,290
+85
+0.1% +$3.9K 0.47% 46
2021
Q2 		$9.16M Buy
161,205
+144
+0.1% +$10.2K 0.6% 40
2021
Q1 		$12.1M Buy
161,061
+256
+0.2% +$21K 0.88% 35
2020
Q4 		$13.9M Buy
160,805
+3,535
+2% +$261K 1.07% 34
2020
Q3 		$9.61M Buy
157,270
+86,887
+123% +$4.4M 0.85% 34
2020
Q2 		$2.93M Buy
70,383
+15,559
+28% +$565K 0.28% 48
2020
Q1 		$1.57M Sell
54,824
-12,789
-19% -$741K 0.24% 54
2019
Q4 		$4.88M Buy
67,613
+53,603
+383% +$6.59M 0.62% 39
2019
Q3 		$1.97M Buy
14,010
+107
+0.8% +$17.9K 0.57% 33
2019
Q2 		$2.54M Sell
13,903
-46
-0.3% -$7.85K 0.74% 26
2019
Q1 		$2.22M Buy
13,949
+2,033
+17% +$294K 0.67% 30
2018
Q4 		$1.14M Buy
11,916
+3,216
+37% +$368K 0.4% 41
2018
Q3 		$961K Hold
8,700
– – 0.59% 34
2018
Q2 		$1.36M Buy
+8,700
New +$1.37M 0.47% 34

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristotle Atlantic Partners's SAGE Position: Q3 2023 in Review

Aristotle Atlantic Partners sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 197,626 shares — an estimated $9.29M sold.

Aristotle Atlantic Partners first reported a position in SAGE in Q2 2018 and held it in 21 quarters. The position peaked at $13.9M in Q4 2020. 193 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

  • Aristotle Atlantic Partners reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Aristotle Atlantic Partners sold 197,626 Sage Therapeutics shares in Q3 2023, an estimated $9.29M.
  • Aristotle Atlantic Partners first reported a position in Sage Therapeutics in Q2 2018 and held it in 21 quarters.
  • Aristotle Atlantic Partners's Sage Therapeutics position peaked at $13.9M in Q4 2020.
  • 193 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Aristotle Atlantic Partners's 13F filing for Q3 2023, filed 14 Nov 2023.